Many With Relapsed/Refractory Lymphoma in Pregnancy Delay Treatment
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, June 6, 2023 -- Most women with relapsed/refractory lymphoma during pregnancy defer therapy and there are few obstetric or neonatal complications, according to a study published online June 1 in Blood Advances.
Faheem Farooq, M.D., from Rutgers Cancer Institute of New Jersey in New Brunswick, and colleagues conducted a retrospective analysis across 10 international centers involving 23 patients with relapsed/refractory lymphoma during pregnancy. Of the patients, 18 had classic Hodgkin lymphoma, two had peripheral T-cell lymphoma, and one each had diffuse large B-cell, follicular, and marginal zone lymphoma.
The researchers found that most patients chose to delay therapy until postpartum while under close surveillance, while five of the patients received intentional antenatal therapy at a median of 26 weeks of gestation; one of these received checkpoint inhibitor therapy. Nineteen live births occurred; most were born via vaginal delivery. More than half of the births were preterm (median gestation, 36 weeks), with most initiated by clinicians. The median birthweight was 2,777 g; no malformations or genetic diseases were identified. Nine patients underwent transplant postpartum. Three-year progression-free and overall survival were 24 and 83 percent, respectively, with median follow-up of 37 months.
"The goal of this study is to provide data that can inform patients and providers," a coauthor said in a statement. "While a relapsed/refractory lymphoma diagnosis during pregnancy is rare, we hope to ensure that oncologists and women have some form of guidance on how to approach this complex clinical scenario."
Several authors disclosed ties to the pharmaceutical and biotechnology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Tattoos May Increase Risk of Malignant Lymphoma
WEDNESDAY, May 29, 2024 -- Tattoo exposure is associated with an increased risk of several malignant lymphoma subtypes, according to a study published online in the June issue...
American College of Obstetricians and Gynecologists, May 17-19
The annual meeting of the American College of Obstetricians and Gynecologists was held from May 17 to 19 in San Francisco and was attended by more than 4,000 clinicians...
Epidural Analgesia Linked to Decline in Severe Maternal Morbidity
FRIDAY, May 24, 2024 -- Epidural analgesia during labor is associated with a reduction in severe maternal morbidity (SMM), according to a study published online May 22 in The...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.